The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Impact of Diabetes Mellitus on Bone Health
Open accessAbstract
Long-term exposure to a diabetic environment leads to changes in bone metabolism and impaired bone micro-architecture through a variety of mechanisms on molecular and structural levels. These changes predispose the bone to an increased fracture risk and impaired osseus healing. In a clinical practice, adequate control of diabetes mellitus is essential for preventing detrimental effects on bone health. Alternative fracture risk assessment tools may be needed to accurately determine fracture risk in patients living with diabetes mellitus. Currently, there is no conclusive model explaining the mechanism of action of diabetes mellitus on bone health, particularly in view of progenitor cells. In this review, the best available literature on the impact of diabetes mellitus on bone health in vitro and in vivo is summarised with an emphasis on future translational research opportunities in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769 · cited 2×
“Recent scientific developments in the understanding of the molecular pathways involved in diabetes mellitus have opened opportunities in new anti-inflammatory treatment approaches [173].”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Adipose tissue dysfunction as determinant of obesity-associated metabolic complications
Longo, M., Zatterale, F., Naderi, J., Parrillo, L., Formisano, P., Raciti, G. A., Beguinot, F., & Miele, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092358 · Cited by 1,575
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G., Cooper, M. E., & Brownlee, M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081188 · Cited by 1,115
Mechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
Lee, Y. S., Kim, J.-W., Osborne, O., Oh, D. Y., Sasik, R., Schenk, S., Chen, A., Chung, H., Murphy, A., Watkins, S. M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.012 · Cited by 598
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Influence of nonenzymatic glycation on biomechanical properties of cortical bone
Vashishth, D., Gibson, G. J., Khoury, J. I., Schaffler, M. B., Kimura, J., & Fyhrie, D. P. (2001) · Bone · doi:10.1016/s8756-3282(00)00434-8 · Cited by 525
Wang, B., Wood, I. S., & Trayhurn, P. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-007-0301-8 · Cited by 392
Bone turnover markers: Emerging tool in the management of osteoporosis
Shetty, S., Kapoor, N., Bondu, J. D., Thomas, N., & Paul, T. V. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.192914 · Cited by 330 · cited 2×
“Alternatively, sclerostin is a marker for bone resorption [81] and is inversely correlated to bone turnover markers for bone formation in patients living with T2DM [88–90].”
BackgroundRota, M., LeCapitaine, N., Hosoda, T., Boni, A., De Angelis, A., Padin-Iruegas, M. E., Esposito, G., Vitale, S., Urbanek, K., Casarsa, C., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000231289.63468.08 · Cited by 330
Athinarayanan, S. J., Adams, R. N., Hallberg, S. J., McKenzie, A. L., Bhanpuri, N. H., Campbell, W. W., Volek, J. S., Phinney, S. D., & McCarter, J. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00348 · Cited by 324
Epigenetic phenomena linked to diabetic complications
Pirola, L., Balcerczyk, A., Okabe, J., & El-Osta, A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.188 · Cited by 239
Unlocking the biology of RAGE in diabetic microvascular complications
Manigrasso, M. B., Juranek, J., Ramasamy, R., & Schmidt, A. M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.08.002 · Cited by 209
Gallagher, K. A., Joshi, A., Carson, W. F., Schaller, M., Allen, R., Mukerjee, S., Kittan, N., Feldman, E. L., Henke, P. K., Hogaboam, C., et al. (2015) · Diabetes · doi:10.2337/db14-0872 · Cited by 206
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200 · cited 1×
“In murine models, the administration of the glucagon-like peptide 1 (GLP1) , which 372 is a hormone that facilitates the ‘incretin effect,’ has been shown to increase bone formation markers 373 [207] and prevent the deterioration of the bone micro-architecture [208].”
BackgroundMabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Frid, A., Sterner, G. N., Löndahl, M., Wiklander, C., Cato, A., Vinge, E., & Andersson, A. (2010) · Diabetes Care · doi:10.2337/dc09-1284 · Cited by 126
Zhang, Y. S., Weng, W. Y., Xie, B. C., Meng, Y., Hao, Y. H., Liang, Y. M., & Zhou, Z. K. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4649-8 · Cited by 93
Cited by
Smart Hydrogels for Advanced Drug Delivery Systems
Bordbar-Khiabani, A., & Gasik, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073665 · Cited by 382
Fracture Healing in the Setting of Endocrine Diseases, Aging, and Cellular Senescence
Saul, D., & Khosla, S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac008 · Cited by 185
Metadata
- Authors
- Murray, C. E., & Coleman, C. M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-09-30
- Volume
- 20
- Issue
- 19
- Pages
- 4873
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2976773901
- Cited by
- 228
- References
- 23
- FWCI
- 18.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.